News
Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally ...
Q3 2025 Earnings Call Transcript July 10, 2025 Marc Stephen Spezialy: Good morning, everybody, and welcome to Pure Cycle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback